Compare · AZN vs GNLX
AZN vs GNLX
Side-by-side comparison of AstraZeneca PLC (AZN) and Genelux Corporation (GNLX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and GNLX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $263.10B, about 2137.8x GNLX ($123.1M).
- Over the past year, AZN is down 9.9% and GNLX is down 28.4% - AZN leads by 18.5 points.
- AZN has been more active in the news (14 items in the past 4 weeks vs 5 for GNLX).
- AZN has more recent analyst coverage (25 ratings vs 6 for GNLX).
- Company
- AstraZeneca PLC
- Genelux Corporation
- Price
- $169.66+1.75%
- $2.71-0.37%
- Market cap
- $263.10B
- $123.1M
- 1M return
- -0.09%
- -7.34%
- 1Y return
- -9.89%
- -28.36%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- 2023
- News (4w)
- 14
- 5
- Recent ratings
- 25
- 6
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Latest AZN
- TROPION-Urothelial04 Phase 3 Trial of Datroway® Initiated as Adjuvant Therapy in Patients with High-Risk Muscle Invasive Urothelial Cancer
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
- ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated statistically significant and clinically meaningful improvement in PFS as 1st-line treatment of patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- TAGRISSO® (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO
- Enhertu® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival as First-Line Treatment of Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 Trial
Latest GNLX
- Genelux Corporation Reports Second Quarter Financial Results and Provides Business Updates
- SEC Form 10-Q filed by Genelux Corporation
- Chief Technical Officer Cappello Joseph sold $1,924 worth of shares (653 units at $2.95), decreasing direct ownership by 0.20% to 328,737 units (SEC Form 4)
- President and CEO Zindrick Thomas sold $8,905 worth of shares (3,023 units at $2.95), decreasing direct ownership by 0.24% to 1,260,890 units (SEC Form 4)
- Chief Scientific Officer Yu Yong sold $1,922 worth of shares (653 units at $2.94), decreasing direct ownership by 0.24% to 268,371 units (SEC Form 4)
- Attovia Therapeutics Appoints John W. Smither to Board of Directors
- Director Smither John W sold $34,898 worth of shares (12,000 units at $2.91), decreasing direct ownership by 12% to 91,403 units (SEC Form 4)
- Genelux Announces Publication of Translational Analysis Supporting Immune Activation and Chemotherapy Sensitization with Olvi‑Vec in Ovarian Cancer
- SEC Form 8-K filed by Genelux Corporation
- President and CEO Zindrick Thomas was granted 730,601 shares, increasing direct ownership by 137% to 1,263,913 units (SEC Form 4)